CIBC World Markets Inc. lessened its position in Edwards Lifesciences Corp (NYSE:EW) by 17.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,950 shares of the medical research company’s stock after selling 403 shares during the period. CIBC World Markets Inc.’s holdings in Edwards Lifesciences were worth $220,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Victory Capital Management Inc. raised its position in shares of Edwards Lifesciences by 4.6% in the third quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock valued at $60,969,000 after buying an additional 24,399 shares during the last quarter. Korea Investment CORP raised its position in shares of Edwards Lifesciences by 144.5% in the third quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock valued at $38,880,000 after buying an additional 210,200 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Edwards Lifesciences by 53.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock valued at $1,418,000 after buying an additional 4,170 shares during the last quarter. Oakbrook Investments LLC raised its position in shares of Edwards Lifesciences by 25.7% in the third quarter. Oakbrook Investments LLC now owns 19,050 shares of the medical research company’s stock valued at $2,082,000 after buying an additional 3,900 shares during the last quarter. Finally, ING Groep NV raised its position in shares of Edwards Lifesciences by 41.2% in the third quarter. ING Groep NV now owns 22,905 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 6,684 shares during the last quarter. 81.11% of the stock is owned by institutional investors and hedge funds.

Shares of Edwards Lifesciences Corp (EW) opened at $126.27 on Monday. Edwards Lifesciences Corp has a twelve month low of $89.20 and a twelve month high of $138.48. The stock has a market cap of $26,721.24, a P/E ratio of 33.23, a P/E/G ratio of 1.86 and a beta of 0.63. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.81 and a quick ratio of 1.41.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same period in the previous year, the firm earned $0.75 earnings per share. Edwards Lifesciences’s revenue was up 15.7% compared to the same quarter last year. equities analysts anticipate that Edwards Lifesciences Corp will post 4.49 EPS for the current year.

Edwards Lifesciences announced that its board has initiated a stock repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

In other Edwards Lifesciences news, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $104.76, for a total transaction of $1,986,249.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $106.86, for a total transaction of $3,515,694.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 175,940 shares of company stock valued at $20,049,578. 2.13% of the stock is owned by insiders.

A number of equities analysts have recently weighed in on EW shares. Canaccord Genuity reissued a “buy” rating and issued a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Barclays cut their price objective on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 25th. Morgan Stanley cut their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Finally, Deutsche Bank cut their price objective on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Three research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $141.15.

TRADEMARK VIOLATION NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/02/12/cibc-world-markets-inc-has-220000-stake-in-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.